Cypress’ On-Time Chances For Milnacipran Look Good
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s nod for Cymbalta boosts odds for the next fibromyalgia drug to hit its end-of-October PDUFA date.
You may also be interested in...
FDA Puts Off Forest’s Fibromyalgia Drug Milnacipran
For unknown reasons, SSNRI spending weeks in regulatory limbo.
FDA Puts Off Forest’s Fibromyalgia Drug Milnacipran
For unknown reasons, SSNRI spending weeks in regulatory limbo.
Antipsychotic Not Certain Savior For Forest
Cariprazine shows potential in top-line Phase II, as milnacipran PDUFA date – and firm’s patent cliff – grow near.